uniQure (NASDAQ:QURE) Earns Buy Rating from HC Wainwright

uniQure (NASDAQ:QURE)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $70.00 price objective on the biotechnology company’s stock. HC Wainwright’s price objective would suggest a potential upside of 478.99% from the company’s previous close.

QURE has been the topic of several other research reports. Mizuho lifted their price objective on shares of uniQure from $7.00 to $20.00 and gave the stock a “neutral” rating in a research note on Thursday, December 19th. Cantor Fitzgerald lifted their price objective on shares of uniQure from $28.00 to $58.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 10th. StockNews.com raised shares of uniQure to a “sell” rating in a research note on Wednesday, February 5th. Guggenheim reiterated a “buy” rating on shares of uniQure in a report on Wednesday, December 11th. Finally, The Goldman Sachs Group raised their target price on shares of uniQure from $9.00 to $20.00 and gave the stock a “neutral” rating in a report on Thursday, December 12th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, uniQure has a consensus rating of “Moderate Buy” and a consensus price target of $38.89.

uniQure Stock Performance

Shares of QURE opened at $12.09 on Tuesday. The firm’s 50 day moving average is $14.69 and its 200-day moving average is $9.91. The stock has a market capitalization of $589.30 million, a P/E ratio of -2.44 and a beta of 0.38. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51. uniQure has a 12-month low of $3.73 and a 12-month high of $19.18.

Insiders Place Their Bets

In other news, CFO Christian Klemt sold 2,916 shares of the stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $11.32, for a total value of $33,009.12. Following the completion of the sale, the chief financial officer now owns 155,168 shares of the company’s stock, valued at approximately $1,756,501.76. This represents a 1.84 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Matthew C. Kapusta sold 28,341 shares of the stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $10.29, for a total value of $291,628.89. Following the completion of the sale, the chief executive officer now directly owns 651,454 shares of the company’s stock, valued at approximately $6,703,461.66. The trade was a 4.17 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 96,044 shares of company stock valued at $1,001,040 in the last quarter. 4.74% of the stock is currently owned by insiders.

Institutional Investors Weigh In On uniQure

A number of large investors have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. increased its position in uniQure by 9.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,062 shares of the biotechnology company’s stock worth $195,000 after buying an additional 969 shares during the period. Tudor Investment Corp ET AL boosted its stake in uniQure by 5.9% in the fourth quarter. Tudor Investment Corp ET AL now owns 24,784 shares of the biotechnology company’s stock valued at $438,000 after buying an additional 1,371 shares in the last quarter. Wells Fargo & Company MN boosted its stake in uniQure by 13.9% in the fourth quarter. Wells Fargo & Company MN now owns 12,294 shares of the biotechnology company’s stock valued at $217,000 after buying an additional 1,503 shares in the last quarter. Northern Trust Corp boosted its stake in shares of uniQure by 2.1% during the fourth quarter. Northern Trust Corp now owns 95,591 shares of the biotechnology company’s stock valued at $1,688,000 after purchasing an additional 1,923 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of uniQure by 6.0% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,978 shares of the biotechnology company’s stock valued at $1,253,000 after purchasing an additional 3,996 shares in the last quarter. Institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.